clinical trial · NCT05170048
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
Evergreen Therapeutics, Inc.·phase2·not yet recruiting·n = 90
Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)EG-301AREDS2 supplements
brief summary
This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD). Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are: 1. AREDS2 supplements (Control Group, N=30) 2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)
started
Jun 1, 2026
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Dec 8, 2025
official title
A Phase 2, Parallel, Randomized, Open-label, Controlled Study of EG-301 150 mg Daily in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol